BRPI0516872A - uso de compostos orgánicos - Google Patents

uso de compostos orgánicos

Info

Publication number
BRPI0516872A
BRPI0516872A BRPI0516872-4A BRPI0516872A BRPI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A BR PI0516872 A BRPI0516872 A BR PI0516872A
Authority
BR
Brazil
Prior art keywords
organic compounds
calcitonin
relates
patients
specifically
Prior art date
Application number
BRPI0516872-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Moise Azria
Claus Christiansen
Original Assignee
Nordic Bioscience As
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33443790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nordic Bioscience As, Novartis Ag filed Critical Nordic Bioscience As
Publication of BRPI0516872A publication Critical patent/BRPI0516872A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0516872-4A 2004-10-12 2005-10-10 uso de compostos orgánicos BRPI0516872A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0422644.5A GB0422644D0 (en) 2004-10-12 2004-10-12 Organic compounds
PCT/EP2005/010892 WO2006040114A1 (en) 2004-10-12 2005-10-10 Use of organic compounds

Publications (1)

Publication Number Publication Date
BRPI0516872A true BRPI0516872A (pt) 2008-09-23

Family

ID=33443790

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516872-4A BRPI0516872A (pt) 2004-10-12 2005-10-10 uso de compostos orgánicos

Country Status (13)

Country Link
US (1) US20090048157A1 (enExample)
EP (1) EP1802328A1 (enExample)
JP (1) JP2008515947A (enExample)
KR (1) KR20070061864A (enExample)
CN (1) CN101035556A (enExample)
AU (1) AU2005293802A1 (enExample)
BR (1) BRPI0516872A (enExample)
CA (1) CA2580766A1 (enExample)
GB (1) GB0422644D0 (enExample)
MX (1) MX2007004259A (enExample)
RU (1) RU2007117492A (enExample)
TW (1) TW200628168A (enExample)
WO (1) WO2006040114A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618723A2 (pt) * 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado
CA2750035C (en) 2009-01-22 2018-02-27 Unigene Laboratories Inc. Treatment for obesity
KR102019911B1 (ko) * 2011-11-02 2019-09-09 키바이오사이언스 아게 질병 및 장애 치료용 펩타이드 유사체
RS57519B1 (sr) * 2011-11-02 2018-10-31 Keybioscience Ag Mimetici kalcitonina za lečenje bolesti i poremećaja
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
CN107345965A (zh) * 2016-05-04 2017-11-14 广州优迪生物科技有限公司 一种同时检测N-MID和β-CTX的双标记时间分辨荧光免疫分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
EP0726075A1 (en) * 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
IT1282374B1 (it) * 1996-01-31 1998-03-20 Therapicon Srl Composizioni farmaceutiche parenterali a base di calcitonine sintetiche a ph controllato con basso indice di dolorosita'
WO2000059863A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20040110170A1 (en) * 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
TW200411053A (en) * 2002-12-30 2004-07-01 Ind Tech Res Inst Nucleic acid encoding recombinant salmon calcitionin, expression vector thereof, and method for producing recombinant salmon calcitonin therewith

Also Published As

Publication number Publication date
WO2006040114A1 (en) 2006-04-20
US20090048157A1 (en) 2009-02-19
CN101035556A (zh) 2007-09-12
KR20070061864A (ko) 2007-06-14
RU2007117492A (ru) 2008-11-20
MX2007004259A (es) 2007-05-11
AU2005293802A1 (en) 2006-04-20
JP2008515947A (ja) 2008-05-15
EP1802328A1 (en) 2007-07-04
TW200628168A (en) 2006-08-16
CA2580766A1 (en) 2006-04-20
GB0422644D0 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0615150A2 (pt) agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
BRPI0814299B8 (pt) preparação sólida compreendendo alogliptina e cloridreto de metformina, uso de uma preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
ECSP12007431A (es) Compuestos orgánicos
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
BRPI0516872A (pt) uso de compostos orgánicos
BRPI0612624A2 (pt) métodos para tratar doença vascular em um humano, e para prevenção e/ou tratamento de uma doença induzida por trombose ou uma doença induzida por tromboembolismo em um humano, e, uso de um composto
AR064214A1 (es) Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas
CL2008002884A1 (es) Composicion farmaceutica compuesta por meloxicam o calecoxib y alopurinol; composicion farmaceutica; y uso para el control y tratamiento de la gota, la artritis gotosa y otras patologias relacionadas.
NO20053339L (no) Levalbuterolsalt.
CR11387A (es) Productos quimioterapeuticos cristalinos
BRPI0513825A (pt) combinações de epotilona
CL2007003395A1 (es) Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.
ATE493430T1 (de) Pantropisches hundecoronavirus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.